Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trial

Joseph N Jarvis¹, Roger Chou², Thomas S Harrison³, David S Lawrence⁴, Charles Muthoga⁵, Kennedy Mupeli⁶, David B Meya⁷, Henry C Mwandumba⁸, Cecilia Kanyama⁹, Graeme Meintjes¹⁰, Tshepo B Leeme¹¹, Chiratidzo E Ndhlovu¹², Pauline Beattie¹³, Omar Sued¹⁴, Carmen Pérez Casas¹⁵, Michael Makanga¹³, Nathan Ford¹⁶

Affiliations

¹ Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Electronic address: joseph.jarvis@lshtm.ac.uk.
² Pacific Northwest Evidence-based Practice Center, Oregon Health & Science University, Portland, OR, USA.
³ Institute of Infection and Immunity, St George's University London, London, UK; The Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, UK.
⁴ Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
⁵ Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
⁶ The Center for Youth of Hope, Gaborone, Botswana.
⁷ Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
⁸ Liverpool School of Tropical Medicine, Liverpool, UK; Malawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
⁹ Lilongwe Medical Relief Trust, University of North Carolina Project, Lilongwe, Malawi.
¹⁰ The Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Medicine, University of Cape Town, Cape Town, South Africa.
¹¹ Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
¹² Internal Medicine Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
¹³ European & Developing Countries Clinical Trials Partnership, Hague, Netherlands.
¹⁴ Pan American Health Organization, Washington, DC, USA.
¹⁵ Unitaid, Geneva, Switzerland.
¹⁶ Department of Global HIV, Viral Hepatitis and Sexually Transmitted Infections Programmes, WHO, Geneva, Switzerland.

PMID: 37858577
PMCID: PMC7615252
DOI: 10.1016/S2214-109X(23)00412-6

Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trial

Joseph N Jarvis et al. Lancet Glob Health. 2023 Nov.

. 2023 Nov;11(11):e1688-e1690.

doi: 10.1016/S2214-109X(23)00412-6.

Authors

Affiliations

¹ Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Electronic address: joseph.jarvis@lshtm.ac.uk.
² Pacific Northwest Evidence-based Practice Center, Oregon Health & Science University, Portland, OR, USA.
³ Institute of Infection and Immunity, St George's University London, London, UK; The Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, UK.
⁴ Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
⁵ Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
⁶ The Center for Youth of Hope, Gaborone, Botswana.
⁷ Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
⁸ Liverpool School of Tropical Medicine, Liverpool, UK; Malawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
⁹ Lilongwe Medical Relief Trust, University of North Carolina Project, Lilongwe, Malawi.
¹⁰ The Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Medicine, University of Cape Town, Cape Town, South Africa.
¹¹ Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
¹² Internal Medicine Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
¹³ European & Developing Countries Clinical Trials Partnership, Hague, Netherlands.
¹⁴ Pan American Health Organization, Washington, DC, USA.
¹⁵ Unitaid, Geneva, Switzerland.
¹⁶ Department of Global HIV, Viral Hepatitis and Sexually Transmitted Infections Programmes, WHO, Geneva, Switzerland.

PMID: 37858577
PMCID: PMC7615252
DOI: 10.1016/S2214-109X(23)00412-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

We would like to thank all investigators and participants in the AMBITION trial and associated substudies, community members, and the funders of the trial. The AMBITION trial was supported by a grant through the European Developing Countries Clinical Trials Partnership (EDCTP), the Swedish International Development Cooperation Agency (TRIA2015-1092), and the Wellcome Trust/Medical Research Council (MRC) UK/UKAID Joint Global Health Trials (MR/P006922/1). Additional funding was provided by the National Institute for Health Research (NIHR) through a Global Health Research Professorship (RP-2017-08-ST2-012, to JNJ) with aid from the UK Government to support global health research. JNJ is funded by the National Institute for Health and Care Research (NIHR) through a Global Health Research Professorship (RP-2017-08-ST2-012) using UK aid from the UK Government to support global health research and received grant payments from the NIHR and EDCTP to his institution. RC received consulting fees to serve as methodologist for the updated WHO guideline on cryptococcal meningitis. TSH and DSL received support for the underlying AMBITION trial to institution from EDCTP, MRC, and Wellcome Trust, UK aid from the UK Government to support global health research, and provision of drug for the underlying AMBITION trial from Gilead. All other authors declare no competing interests. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The writing of this Comment was supported by a grant from the Bill & Melinda Gates Foundation. We are grateful to Susan L Norris and Rebekah Thomas for providing comments on an earlier draft.

References

1. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510–20. - PMC - PubMed
1. Jarvis JN, Lawrence DS, Meya DB, et al. Single-dose liposomal amphotericin b treatment for cryptococcal meningitis. N Engl J Med. 2022;386:1109–20. - PMC - PubMed
1. WHO. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. 2022. Jun 27, [accessed Sept 22, 2023]. https://www.who.int/publications/i/item/9789240052178 . - PubMed
1. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984;3:409–22. - PubMed
1. Rajasingham R, Govender NP, Jordan A, et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis. 2022;22:1748–55. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trial

Affiliations

Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trial

Authors

Affiliations

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical